(S)-Lomedeucitinib ((S)-BMS-986322) is a S-enantiomer of Lomedeucitinib. Lomedeucitinib is a tyrosine protein kinase ( TYK2 ) inhibitor [1].
References:
[1]. Drakos A, et al. Emerging Oral Therapies for the Treatment of Psoriasis: A Review of Pipeline Agents[J]. Pharmaceutics, 2024, 16(1): 111.
References:
[1]. Drakos A, et al. Emerging Oral Therapies for the Treatment of Psoriasis: A Review of Pipeline Agents[J]. Pharmaceutics, 2024, 16(1): 111.
















